Alamar Biosciences, Inc. (California) (ALMR)
30.69
+0.97
(+3.26%)
USD |
NASDAQ |
Oct 23, 16:00
30.69
0.00 (0.00%)
After-Hours: 20:00
Alamar Biosciences Enterprise Value : 1.931B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.931B |
| October 22, 2026 | 1.864B |
| October 21, 2026 | 1.984B |
| October 20, 2026 | 1.755B |
| October 19, 2026 | 1.626B |
| October 16, 2026 | 1.555B |
| October 15, 2026 | 1.704B |
| October 14, 2026 | 1.562B |
| October 13, 2026 | 1.433B |
| October 12, 2026 | 1.483B |
| October 09, 2026 | 1.555B |
| October 08, 2026 | 1.599B |
| October 07, 2026 | 1.728B |
| October 06, 2026 | 2.040B |
| October 05, 2026 | 2.447B |
| October 02, 2026 | 2.186B |
| October 01, 2026 | 2.054B |
| September 30, 2026 | 2.165B |
| September 29, 2026 | 2.067B |
| September 28, 2026 | 2.064B |
| September 25, 2026 | 2.077B |
| September 24, 2026 | 2.105B |
| September 23, 2026 | 2.031B |
| September 22, 2026 | 2.106B |
| September 21, 2026 | 2.233B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.220B |
| September 17, 2026 | 2.022B |
| September 16, 2026 | 1.840B |
| September 15, 2026 | 1.796B |
| September 14, 2026 | 1.744B |
| September 11, 2026 | 1.737B |
| September 10, 2026 | 1.728B |
| September 09, 2026 | 1.811B |
| September 08, 2026 | 1.880B |
| September 04, 2026 | 1.938B |
| September 03, 2026 | 1.923B |
| September 02, 2026 | 1.917B |
| September 01, 2026 | 1.839B |
| August 31, 2026 | 1.920B |
| August 28, 2026 | 1.932B |
| August 27, 2026 | 2.091B |
| August 26, 2026 | 2.166B |
| August 25, 2026 | 2.093B |
| August 24, 2026 | 2.070B |
| August 21, 2026 | 2.177B |
| August 20, 2026 | 2.205B |
| August 19, 2026 | 2.267B |
| August 18, 2026 | 2.088B |
| August 17, 2026 | 2.031B |
| August 14, 2026 | 2.102B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Personalis, Inc. | 1.511B |
| 10X Genomics, Inc. | 8.848B |
| Champions Oncology, Inc. | 72.87M |
| Medpace Holdings, Inc. | 18.13B |
| Avantor, Inc. | 15.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.20M |
| Revenue (Quarterly) | 29.43M |
| Total Expenses (Quarterly) | 42.63M |
| EPS Diluted (Quarterly) | -0.1902 |
| Gross Profit Margin (Quarterly) | 60.21% |
| Profit Margin (Quarterly) | -44.85% |
| Earnings Yield | -2.31% |
| Normalized Earnings Yield | -1.984 |